Beam Therapeutics Inc.
BEAM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BEAM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BEAM
Beam Therapeutics Inc. is a biotech company developing precision genetic medicines through base editing technology, with clinical programs in sickle cell disease, alpha-1 antitrypsin deficiency, and glycogen storage disease type 1a.
Key risk: Clinical development delays
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 5 clinical trials for Beam Therapeutics Inc..
Beam Therapeutics Inc. is a biotech company developing precision genetic medicines through base editing technology, with clinical programs in sickle cell disease, alpha-1 antitrypsin deficiency, and glycogen storage disease type 1a.
- Beam Therapeutics is focused on base editing, a technology that makes single-letter changes to DNA or RNA without double-strand breaks [sec].
- As of 2026-06-30, the company reported cash & equivalents of $226.5M, total revenue of $0.5M, and a net loss of $122.7M [sec].
- Lead clinical programs include risto-cel (formerly BEAM-101) for sickle cell disease, BEAM-103 for beta thalassemia, BEAM-301 for glycogen storage disease type 1a, and BEAM-302 for alpha-1 antitrypsin deficiency [sec].
- The company expects operating expenses to increase over the next twelve months due to clinical development and BLA readiness activities [sec_mda].
- Beam has not yet commercialized any product candidates and does not expect to generate product revenue in the near future [sec_mda].
What works
- Beam's base editing platform offers a differentiated approach to genetic medicine, potentially enabling precise corrections with fewer off-target effects [sec].
- The company has multiple clinical-stage programs targeting large patient populations, including sickle cell disease and alpha-1 antitrypsin deficiency [sec].
- Beam is investing in a commercial-scale cGMP manufacturing facility, indicating readiness for potential future commercialization [sec_mda].
What to weigh
- Beam has not yet commercialized any product candidates and does not expect to generate product revenue in the near future [sec_mda].
- The company reported a net loss of $122.7M for the six months ended June 30, 2026, and may need to raise additional capital to fund operations [sec].
- Beam faces significant risks related to clinical development, regulatory approval, and competition, which could delay or prevent product success [sec].
- The company's cash and equivalents of $226.5M as of June 30, 2026, may be insufficient to fund all planned activities without additional financing [sec_mda].
From the filings
Quoted directly from source documents.
Beam's technology involves base editing, which makes single-letter changes without double-strand breaks.
“the therapeutic applications and potential of the Company's technology, including with respect to SCD, AATD and GSD1a”
SEC filings · January 12, 2026
The company expects operating expenses to increase due to clinical development and BLA readiness.
“operating expenses to increase over the next twelve months, as we expect increases in costs related to continued and expected clinical-stage development of our lead product candidates and increases in BLA readiness activities related to the potential commercial launch of clinical products, if approved.”
SEC MD&A · August 4, 2026
Beam has not commercialized any product and does not expect near-term product revenue.
“We have not yet commercialized any of our product candidates, and we do not expect to generate revenue from the sale of our product candidates in the near future.”
SEC MD&A · May 7, 2026
Beam may need to raise additional capital to fund operations.
“We anticipate that we may need to raise additional capital in order to continue to fund our research and development, including our planned preclinical studies and clinical trials, maintaining and operating our commercial-scale cGMP manufacturing facility, and new product development, as well as to fund our general operations.”
SEC MD&A · May 7, 2026
Risks & what to watch (4)›
Key risks
- Clinical development delays — Risks that clinical trials may take longer or cost more than planned, potentially delaying regulatory approval [sec].
- Need for additional funding — The company may exhaust capital resources sooner than expected and may not be able to raise additional funds [sec_mda].
- Regulatory and commercialization hurdles — Beam has no approved products and faces uncertainties in obtaining regulatory approval and commercializing [sec].
- Intellectual property risks — The company's ability to obtain, maintain, and enforce patents is uncertain, which could affect competitive position [sec].
What to watch
- Clinical data readouts for risto-cel (sickle cell disease) and BEAM-302 (alpha-1 antitrypsin deficiency) [sec].
- Regulatory interactions and filings for lead programs, including potential BLA submissions [sec_mda].
- Cash runway and any additional financing activities, given the net loss and cash position [sec].
- Progress in manufacturing scale-up at the cGMP facility [sec_mda].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Beam Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Beam Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
50.8 months
D/E 0.30 · 0% dilution
Lead: Phase 1/Phase 2
1 candidate
No upcoming catalysts tracked
0 buys · 15 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
250
Total value held
$2.45B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 12,452,199 | $296.7M |
| ark investment management llc | 12,133,433 | $289.1M |
| farallon capital management llc | 10,134,696 | $241.5M |
| vanguard capital management llc | 8,754,748 | $208.6M |
| blackrock, inc. | 8,487,569 | $202.3M |
| state street corp | 5,699,265 | $135.8M |
| vanguard portfolio management llc | 4,570,797 | $108.9M |
| arch venture management, llc | 4,540,132 | $108.2M |
| amova asset management americas, inc. | 3,825,585 | $91.2M |
| geode capital management, llc | 2,418,592 | $57.6M |
Showing top 10 of 250 institutional holders of Beam Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 31.5%
- Days to cover
- 9.7
- Shares short
- 20,936,705
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BEAM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Beam Therapeutics Inc.?
Beam Therapeutics Inc. is a biotech company developing precision genetic medicines through base editing technology, with clinical programs in sickle cell disease, alpha-1 antitrypsin deficiency, and glycogen storage disease type 1a.
What is Beam Therapeutics Inc.'s lead drug candidate?
Beam Therapeutics Inc.'s most advanced tracked candidate is BEAM-101 (Phase 1/Phase 2) for Sickle Cell Disease.
Who is the CEO of Beam Therapeutics Inc.?
Mr. John M. Evans M.B.A. is the chief executive officer of Beam Therapeutics Inc. (BEAM).
Where is Beam Therapeutics Inc. headquartered?
Beam Therapeutics Inc. (BEAM) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Beam Therapeutics Inc. focus on?
Beam Therapeutics Inc. develops therapies across Rare Disease, Respiratory, Hematology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.